Patents by Inventor Jinming Zhou
Jinming Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240137581Abstract: The disclosure relates to a method, apparatus, readable medium, and electronic device for live stream interaction. The method includes: in accordance with displaying of a first control at a first target position of a live stream interface, obtaining a first duration during which a user watches the live stream interface; in accordance with a determination that the first duration is greater than or equal to a first predetermined duration threshold, switching the first control to a second control, and displaying the second control at a second target position of the live stream interface; and in response to a first operation command performed by the user on the second control, allocating a virtual resource to the user. In this way, interaction modes of a live stream room are enriched, and an activity level of the live stream room can be improved.Type: ApplicationFiled: December 29, 2023Publication date: April 25, 2024Inventors: Ji LIU, Yu SUN, Weijia KONG, Jinming ZHANG, Lei JIN, Ling YANG, Xue YAO, Sijing WANG, Jinhui GUO, Bing ZHOU, Siqi WANG
-
Publication number: 20230321079Abstract: The present invention provides use of berbamine dihydrochloride in preparation of an Ebola virus inhibitor. In the present invention, the primed glycoprotein of the Ebola virus (EBOV-GPcl) is taken as a target site, and an antiviral active compound with the capability of binding to the EBOV-GPcl, i.e., berbamine dihydrochloride, is obtained through structure-based virtual screening. Berbamine dihydrochloride can specifically inhibit the entry of an Ebola recombinant virus by binding to the target protein EBOV-GPcl, thereby achieving the effect of anti-Ebola virus infection. The half-maximum effect concentration (EC50) of berbamine dihydrochloride against EBOV is 0.49 ?M, which indicates that berbamine dihydrochloride has a strong inhibition effect on EBOV.Type: ApplicationFiled: April 10, 2023Publication date: October 12, 2023Inventors: Shan Cen, Quanjie Li, Dongrong Yi, Yi Shi, Han Wang, Jinming Zhou
-
Patent number: 11654141Abstract: The present invention provides use of berbamine dihydrochloride in preparation of an Ebola virus inhibitor. In the present invention, the primed glycoprotein of the Ebola virus (EBOV-GPcl) is taken as a target site, and an antiviral active compound with the capability of binding to the EBOV-GPcl, i.e., berbamine dihydrochloride, is obtained through structure-based virtual screening. Berbamine dihydrochloride can specifically inhibit the entry of an Ebola recombinant virus by binding to the target protein EBOV-GPcl, thereby achieving the effect of anti-Ebola virus infection. The half-maximum effect concentration (EC50) of berbamine dihydrochloride against EBOV is 0.49 ?M, which indicates that berbamine dihydrochloride has a strong inhibition effect on EBOV.Type: GrantFiled: June 19, 2019Date of Patent: May 23, 2023Assignee: Institute of Medicinal Biotechnology, Chinese Academy of Medical SciencesInventors: Shan Cen, Quanjie Li, Dongrong Yi, Yi Shi, Han Wang, Jinming Zhou
-
Publication number: 20220212697Abstract: Disclosed is a gearbox for rail vehicle, a bogie for rail vehicle and a rail vehicle. The gearbox for rail vehicle includes a primary gearbox (1) configured to connect with a traction motor, and a secondary gearbox (2) arranged on both sides of the primary gearbox (1) along a longitudinal direction of the rail vehicle, wherein a framework bearing beam is formed by connecting the primary gearbox (1) and the secondary gearbox (2), the primary gearbox (1) is configured to transmit power from the traction motor to the secondary gearbox (2), and the secondary gearbox (2) are configured to transmit power from the primary gearbox (1) to wheelsets of the rail vehicle.Type: ApplicationFiled: May 18, 2020Publication date: July 7, 2022Inventors: Shuliang SONG, Zhen CHANG, Yuejun ZHANG, Jinming ZHOU, Tianyi LI
-
Publication number: 20210091964Abstract: The invention discloses a physically unclonable structural-color anti-counterfeiting label with artificial intelligence (AI) authentication, which is formed by doping micron-sized particles into disorderedly arranged monodisperse submicron-sized particles and coating onto a black substrate; alternatively, by doping micron-sized particles and black nanoparticles into disorderedly arranged monodisperse submicron-sized particles and coating onto a substrate. The disordered arrangement of monodisperse submicron-sized microspheres has a special effect on light to make the anti-counterfeiting label show a specific structural color. AI is used to learn the anti-counterfeiting label images obtained from an optical microscope and memorize their structural characteristics to form an anti-counterfeiting label database.Type: ApplicationFiled: August 24, 2020Publication date: March 25, 2021Inventors: Jinming Zhou, Xueying He, Yanan Gu, Heling Zhu
-
Publication number: 20200281916Abstract: The present invention provides use of berbamine dihydrochloride in preparation of an Ebola virus inhibitor. In the present invention, the primed glycoprotein of the Ebola virus (EBOV-GPcl) is taken as a target site, and an antiviral active compound with the capability of binding to the EBOV-GPcl, i.e., berbamine dihydrochloride, is obtained through structure-based virtual screening. Berbamine dihydrochloride can specifically inhibit the entry of an Ebola recombinant virus by binding to the target protein EBOV-GPcl, thereby achieving the effect of anti-Ebola virus infection. The half-maximum effect concentration (EC50) of berbamine dihydrochloride against EBOV is 0.49 ?M, which indicates that berbamine dihydrochloride has a strong inhibition effect on EBOV.Type: ApplicationFiled: June 19, 2019Publication date: September 10, 2020Applicant: INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Shan CEN, Quanjie LI, Dongrong YI, Yi SHI, Han WANG, Jinming ZHOU
-
Patent number: 10507847Abstract: A central traction device for a straddling monorail train includes a traction pin and a traction beam. A central sleeve is provided at the center of the traction beam, and the traction pin is mounted in the central sleeve. An inner cavity of the central sleeve has a corset-shaped structure having large diameters on an upper end and a lower end and a small diameter at a middle part, forming double tapered bevels, and a resilient rubber bush is provided between an inner wall of the central sleeve and the traction pin. The device has a simple and compact overall structure and facilitates connection and separation between the train body and the bogie; by providing the lift assembly, the traction device is fixedly connected to the frame, thus the traction device can be wholly lifted; and operation process and environment of raising and lowering the vehicle are improved.Type: GrantFiled: December 13, 2016Date of Patent: December 17, 2019Assignee: CRRC QINGDAO SIFANG CO., LTD.Inventors: Jinming Zhou, Yuejun Zhang, Huijie Zhang, Lijun Ma, Xiaojun Lv, Haiqin Zhao, Xiaojiang Zhou, Shuliang Song, Wei Zhao, Yujie Shi, Chaozhi Zhai
-
Publication number: 20180345996Abstract: A central traction device for a straddling monorail train includes a traction pin and a traction beam. A central sleeve is provided at the center of the traction beam, and the traction pin is mounted in the central sleeve. An inner cavity of the central sleeve has a corset-shaped structure having large diameters on an upper end and a lower end and a small diameter at a middle part, forming double tapered bevels, and a resilient rubber bush is provided between an inner wall of the central sleeve and the traction pin. The device has a simple and compact overall structure and facilitates connection and separation between the train body and the bogie; by providing the lift assembly, the traction device is fixedly connected to the frame, thus the traction device can be wholly lifted; and operation process and environment of raising and lowering the vehicle are improved.Type: ApplicationFiled: December 13, 2016Publication date: December 6, 2018Applicant: CRRC QINGDAO SIFANG CO., LTD.Inventors: Jinming ZHOU, Yuejun ZHANG, Huijie ZHANG, Lijun MA, Xiaojun LV, Haiqin ZHAO, Xiaojiang ZHOU, Shuliang SONG, Wei ZHAO, Yujie SHI, Chaozhi ZHAI
-
Patent number: 8470889Abstract: The present invention relates to the synthesis of a series of ionone and curcumin derivatives as multi-targeting agents effective against both hormone-sensitive and hormone-independent cancers. In particular, the present invention is directed to a distinct class of bifunctional antiandrogens, which inhibit both AR and IKBkinases (IKK). A series of ionone-based chalcones were synthesized and their in vitro cytotoxicity against prostate cancer cell lines were demonstrated. A series of derivatives formed by reacting ionone-based chalcones and hydrazines demonstrate substantial antiproliferative activities in prostate cancer, breast cancer and lung cancer cell lines.Type: GrantFiled: November 25, 2009Date of Patent: June 25, 2013Assignee: TRT Pharma Inc.Inventors: Jian Hui Wu, GĂ©rald Batist, Jinming Zhou, Guoyan Geng, Rongtuan Lin, Yi Li
-
Publication number: 20110230488Abstract: The present invention relates to the synthesis of a series of ionone and curcumin derivatives as multi-targeting agents effective against both hormone-sensitive and hormone-independent cancers. In particular, the present invention is directed to a distinct class of bifunctional antiandrogens, which inhibit both AR and IKBkinases (IKK). A series of ionone-based chalcones were synthesised and their in vitro cytotoxicity against prostate cancer cell lines were demonstrated. A series of derivatives formed by reacting ionone-based chalcones and hydrazines demonstrate substantial antiproliferative activities in prostate cancer, breast cancer and lung cancer cell lines.Type: ApplicationFiled: November 25, 2009Publication date: September 22, 2011Applicant: TRT PHARMA INC.Inventors: Jian Hui Wu, Gerald Batist, Jinming Zhou, Guoyan Geng, Rongtuan Lin